Evidence map›Paper›PMID 29310568›Full record

SynthesisBMC gastroenterology2018

Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials.

Qingqing Qi, Yan Zhang, Feixue Chen, Xiuli Zuo, Yanqing Li

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 35 citations in OpenAlex.

  1. Irritable bowel syndrome.Nature reviews. Disease primers · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. In Silico Food-Drug Interaction: A Case Study of Eluxadoline and Fatty Meal.International journal of molecular sciences · 2020
    Article
  7. Review
  8. Observational
  9. Potential neuro-immune therapeutic targets in irritable bowel syndrome.Therapeutic advances in gastroenterology · 2020
    Review
  10. Update on Pharmacotherapy for Irritable Bowel Syndrome.Current gastroenterology reports · 2019
    Review
  11. Sex-Gender Differences in Irritable Bowel Syndrome.Journal of neurogastroenterology and motility · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Qingqing QiDepartment of Gastroenterology, Qilu Hospital, Shandong University, 107 Wenhuaxi Road, Jinan, Shandong Province, 250012, China.
Yan ZhangDepartment of Gastroenterology, Qilu Hospital, Shandong University, 107 Wenhuaxi Road, Jinan, Shandong Province, 250012, China.
Feixue ChenDepartment of Gastroenterology, Qilu Hospital, Shandong University, 107 Wenhuaxi Road, Jinan, Shandong Province, 250012, China.
Xiuli ZuoDepartment of Gastroenterology, Qilu Hospital, Shandong University, 107 Wenhuaxi Road, Jinan, Shandong Province, 250012, China.
Yanqing LiDepartment of Gastroenterology, Qilu Hospital, Shandong University, 107 Wenhuaxi Road, Jinan, Shandong Province, 250012, China. liyanqing@sdu.edu.cn.
Qilu Hospital of Shandong University · CN

Funding

National Natural Science Foundation of China 81330012National Natural Science Foundation of China 81370495
6 · The paper itself

Abstract

backgroundRamosetron is a potent and selective serotonin type 3 receptor antagonist. This meta-analysis aimed to analyze the efficacy and safety of ramosetron for irritable bowel syndrome with diarrhea (IBS-D).

methodsPubmed, MEDLINE, EMBASE and the Cochrane Library were searched for randomized controlled trials investigating the efficacy and safety of ramosetron for IBS-D. Risk of bias was assessed as described in the Cochrane handbook. A random effects model was used to calculate the effects of ramosetron vs placebo on symptomatic improvements, including relief of overall IBS symptoms, relief of abdominal discomfort/pain, improvement in abnormal bowel habits, and improvement in stool consistency, expressed as pooled relative risks (RRs) with 95% confidence interval (CI). Adverse events data were also summarized with RRs.

resultsFour randomized controlled trials involving 1623 participants were included. Compared with placebo, ramosetron could lead to relief of overall IBS symptoms (RR 1.70; 95%CI 1.48, 1.95), relief of abdominal discomfort/pain (RR 1.41; 95%CI, 1.24, 1.59), improvement in abnormal bowel habits (RR 1.72; 95%CI, 1.50, 1.98) and improvement in stool consistency (RR 1.71; 95%CI 1.40, 2.08). Ramosetron could lead to relief of overall IBS symptoms in both male and female patients (RR; 95%CI: 1.94; 1.58, 2.38 and 1.49; 1.25, 1.79). The RR (95%CI) for reported adverse events of ramosetron vs placebo was 1.10 (0.97, 1.26) across all studies. No serious adverse events (e.g., ischemic colitis) were reported. The incidences of hard stool and constipation were higher in ramosetron group compared with placebo group (RR; 95%CI: 4.74; 3.00, 7.51 and 2.53; 1.57, 4.10, respectively).

conclusionsRamosetron had beneficial effects to both male and female IBS-D patients. Treatment with ramosetron could cause more hard stool and constipation, without severe adverse events.

Indexed as

Abdominal PainBenzimidazolesConstipationDiarrheaHumansIrritable Bowel SyndromeSerotonin 5-HT3 Receptor AntagonistsBenzimidazolesramosetronSerotonin 5-HT3 Receptor AntagonistsEfficacyIrritable bowel syndrome with diarrheaMeta-analysisRamosetronSafety

Identifiers

PMID29310568
PMCPMC5759234
OpenAlexW2782948580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.